STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Rhea-AI Summary
The CHMP adopts a positive opinion recommending the approval of Bristol Myers Squibb's Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. If approved, this regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU. The decision on EU marketing authorization is expected by June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Rhea-AI Summary
Bristol Myers Squibb reported first quarter financial results for 2024, showcasing a 5% increase in revenues to $11.9 billion. Key achievements include U.S. approval of Abecma and Breyanzi, positive proof of concept for Opdualag, and strategic cost-saving initiatives. Despite a GAAP loss per share of $(5.89), the non-GAAP loss per share was $(4.40). The company aims to reinvest cost savings to fuel innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
earnings
-
News
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Rhea-AI Summary
Bristol Myers Squibb and Cellares have entered into a $380M worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies. Cellares will provide its Cell Shuttle platform for Bristol Myers Squibb's clinical and commercial-scale manufacturing needs, enhancing agility, scalability, and turnaround time. This collaboration aims to bring the promise of cell therapies to more patients faster.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
News
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
Rhea-AI Summary
Bristol Myers Squibb (BMY) focuses on advancing patient health globally and enhancing ESG performance. The company aims to address health inequities, expand access to medicines in LMICs, and reduce environmental impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
News
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Rhea-AI Summary
Bristol Myers Squibb presents promising data on KRAZATI (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer at AACR annual meeting. The study shows an objective response rate of 34%, with a median progression-free survival of 6.9 months and median overall survival of 15.9 months. Disease control was observed in 85% of patients, highlighting the potential of adagrasib for this specific patient group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News
Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
Rhea-AI Summary
Bristol Myers Squibb (BMY) releases its 2023 Environmental, Social, and Governance (ESG) Report, highlighting progress in patient access, product innovation, and diversity. The company focuses on advancing patient health, scientific boundaries, and global workforce inclusivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
News
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Rhea-AI Summary
Bristol Myers Squibb (BMY) reports positive interim results from the Phase 3 EMERGENT-4 trial evaluating the long-term efficacy of KarXT in patients with schizophrenia. More than 75% of participants showed significant improvement in symptoms over 52 weeks, with promising safety and tolerability profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Rhea-AI Summary
Bristol Myers Squibb presents favorable long-term metabolic profile and safety data for KarXT in schizophrenia treatment at the Annual Congress of the Schizophrenia International Research Society.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Rhea-AI Summary
Abecma receives FDA approval for earlier use in treating relapsed or refractory multiple myeloma, demonstrating significant progression-free survival benefits and a well-established safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
fda approval
News
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Rhea-AI Summary
Bristol Myers Squibb (BMY) receives expanded approval from the European Commission for Reblozyl (luspatercept) as a first-line treatment for adult patients with transfusion-dependent anemia due to myelodysplastic syndromes. The approval is based on the Phase 3 COMMANDS study, showing Reblozyl's superior efficacy over epoetin alfa in achieving transfusion independence and hemoglobin increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#130 Ranked by Market Cap
#4058 Ranked by Stock Gains
#580 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.